Indications & Evidence for Therapeutic Plasma Exchange
Start with the role of TPE, then the evidence, then the logistics.
The page should open with a simple interpretation of ASFA, because that is how clinicians frame TPE use across specialties. Category I means first-line use, either alone or with other therapy. Category II means accepted second-line use. Category III means the role is not established and use should be individualized. Category IV means the evidence suggests inefficacy or harm. Grade 1 indicates a strong recommendation, Grade 2 a weaker one; A, B, and C reflect the quality of evidence.
Indications & Evidence for Therapeutic Plasma Exchange
Start with the role of TPE, then the evidence, then the logistics.
The page should open with a simple interpretation of ASFA, because that is how clinicians frame TPE use across specialties. Category I means first-line use, either alone or with other therapy. Category II means accepted second-line use. Category III means the role is not established and use should be individualized. Category IV means the evidence suggests inefficacy or harm. Grade 1 indicates a strong recommendation, Grade 2 a weaker one; A, B, and C reflect the quality of evidence.
Filter by specialty, urgency, and evidence strength
ASFA 2023 spans classic first-line indications and highly individualized uses. Use the filters below to find the right starting point for your patient and setting.
Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)
Role: Removes autoantibodies and complement. Equivalent to IVIG efficacy.
Logistics: 5 exchanges over 7-10 days. 1.0-1.5 PV. Peripheral access preferred.
Thrombotic Thrombocytopenic Purpura (TTP)
Role: Essential ADAMTS13 replacement via FFP and removal of anti-ADAMTS13 antibodies.
Logistics: Daily 1.0-1.5 PV with FFP. Urgent initiation and central access required.
ASFA I / 1A
ASFA I / 1A
Evidence first, then workflow
This resource prioritizes high-quality evidence, and clearly labels individualized or investigational use. When evidence is limited, we name that explicitly for transparent team discussion.
Evidence summaries are scoped to bedside decisions: when to start, when to stop, and how to combine TPE with other therapies.
Logistics that change real cases
Access, modality, and nursing capacity determine feasibility. This section highlights operational constraints that commonly derail TPE plans.
- Vascular Access: Catheter selection and site priorities.
- Resource Availability: Machine and nursing staff coordination.
- Coordination: Timing with other procedures like dialysis.
- Product Support: Institutional albumin/FFP protocols.
Neurology
TPE for AIDP, CIDP, NMOSD, and other neurology indications.
Indication Slot
Indication Slot
Hematology
Managing conditions such as TTP, hyperviscosity syndrome, and other hematologic emergencies.
Indication Slot
Evidence first, then workflow
For each indication, this resource prioritizes high-quality evidence where it exists, and clearly labels individualized or investigational use. When evidence is limited, we name that explicitly so you can discuss uncertainty with patients and teams.
Evidence summaries here are scoped to bedside decisions: when to start, when to stop, and how to combine TPE with other therapies.
Logistics that change real cases
Ordering TPE is only the first step. Access, modality, replacement fluid, nursing capacity, and competing ICU priorities all determine whether a plan is feasible. This section highlights operational constraints that commonly derail otherwise appropriate TPE plans.
Vascular Access
Coordination with Dialysis or OR
Machine Availability
Blood Product Support
Neurology
TPE for AIDP, CIDP, NMOSD, and other neurology indications, grouped by urgency and evidence strength.
Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP/GBS)
ASFA Category/Grade: Category I, Grade 1C
Role of TPE: First-line therapy for patients with severe involvement. Recommended to start early in the course of the disease.
Logistics: Typically 5 exchanges over 7-10 days. Central venous access is often required if peripheral access is limited by patient mobility.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
ASFA Category/Grade: Category I, Grade 1B
Role of TPE: Accepted for short-term management of acute relapses or for patients refractory to other therapies.
Logistics: Induction phase involves frequent sessions, transitioning to individualized maintenance. Durable peripheral access is preferred for long-term courses.
Neuromyelitis Optica Spectrum Disorder (NMOSD)
ASFA Category/Grade: Category II, Grade 1C (Acute Attack)
Role of TPE: Used for acute attacks that are steroid-refractory. Earlier initiation is associated with better outcomes.
Logistics: Usually 5-7 exchanges. Replacement fluid is typically 5% Albumin. Monitor for anticoagulation needs in ICU settings.
Hematology
TPE for TTP, HUS, hyperviscosity, and other hematology indications, grouped by urgency and evidence strength.
Thrombotic Thrombocytopenic Purpura (TTP)
Category I | Grade 1A
Role of TPE: Critical for ADAMTS13 replacement and removal of ultra-large VWF multimers and autoantibodies.
Logistics: Immediate/Urgent start. Daily exchange until platelet recovery >150k for 2-3 consecutive days.
Autoimmune Hemolytic Anemia (Warm AIHA)
Category III | Grade 2C
Role of TPE: Refractory cases only. Removes IgG autoantibodies, though efficacy is limited by extravascular distribution.
Logistics: Individualized use. High volumes may be required to clear sufficient antibody load.
Hyperviscosity Syndrome (Waldenström's)
Category I | Grade 1B
Role of TPE: Efficiently reduces IgM concentration to alleviate symptomatic hyperviscosity (retinopathy, CNS symptoms).
Logistics: Typically 1-3 sessions. Monitor serum viscosity levels. Concurrent chemotherapy required.
Catastrophic APS
Category II | Grade 2C
Role of TPE: Part of triple therapy. Removes antiphospholipid antibodies, cytokines, and complement.
Logistics: 3-5 sessions. Always used in combination with anticoagulation and steroids.
Nephrology / Rheumatology
TPE for ANCA-associated vasculitis, anti-GBM disease, lupus nephritis, and other indications, grouped by urgency and evidence strength.
ANCA-associated Vasculitis
Category I | Grade 1A
Used for induction to rapidly remove antibodies and limit end-organ damage, particularly in severe renal or pulmonary involvement.
Logistics: Daily treatments common during induction. Monitor for bleed risk post-biopsy.
Anti-GBM Disease
Category I | Grade 1B
Critical for immediate clearance of pathogenic anti-GBM antibodies to prevent irreversible renal failure or fatal pulmonary hemorrhage.
Logistics: Start today. Do not delay for confirmation if index of suspicion is high.
Lupus Nephritis (Severe)
Category II | Grade 2C
Accepted second-line use for patients with rapidly progressive disease or those refractory to standard immunosuppression.
Logistics: Often individualized treatment. Coordination with Nephro/Rheum is critical.
Transplant
TPE for AMR, GVHD, and other transplant-related indications, grouped by urgency and evidence strength.
Antibody-Mediated Rejection (AMR)
Cat I | Grade 1B
- Role: Primary management for removing donor-specific antibodies (DSA).
- Logistics: Daily or every-other-day sessions; coordinate with IVIG 0.1g/kg post-TPE.
ABO-Incompatible Heart Transplant
Cat II | Grade 2C
- Role: Bridge to transplant when compatible organ is not available.
- Logistics: Pre-operative titles determine frequency; requires central access.
Desensitization (Live Donor Kidney)
Cat I | Grade 1A
- Role: Removing pre-formed antibodies to cross-match compatible status.
- Logistics: Highly scheduled; coordinate with OR timing and transplant surgeon.
Critical Care
TPE for sepsis, cytokine storm, and other critical care indications, grouped by urgency and evidence strength.
Sepsis
ASFA Category III, Grade 2B
Removal of inflammatory cytokines and microbial toxins. Recommended in the early phase of septic shock with multi-organ failure.
Logistics: Continuous vs Intermittent; replacement with 5% Albumin or Plasma dependending on coagulopathy.
Cytokine Storm
ASFA Category III, Grade 2C
Modulation of the hyper-inflammatory state. Useful in secondary HLH or severe CAR-T associated CRS resistant to standard therapies.
Logistics: Coordination with rheumatology or hematology to time TPE after biologic administration.
Acute Liver Failure
ASFA Category I, Grade 1A
High-volume TPE improves transplant-free survival. Removes albumin-bound toxins and replenishes coagulation factors.
Logistics: Central venous pressure monitoring mandatory; replacement with Fresh Frozen Plasma for factor replenishment.
Investigational / Research Use
TPE for indications where evidence is early, conflicting, or currently limited to research protocols, grouped by urgency and evidence strength.
Indication (Placeholder)
ASFA Category III / Grade 2C
Role of TPE is established in institutional research frameworks. Use is individualized based on specific clinical context and alternative therapeutic failure.
Logistics: Central Access required | Frequency: QOD | Duration: Specified by protocol
Condition (Placeholder)
ASFA Category IV / Grade 1C
The role of therapeutic exchange is strictly investigational. Focus on removing neutralizing antibodies within the scope of clinical research studies.
Logistics: Peripheral Access possible | Coordination with clinical trials office required
Indication (Placeholder)
Research Protocol Only
Experimental application where evidence suggests potential role in cytokine management. Rigorous safety monitoring mandated.
Logistics: Multi-disciplinary ICU coordination | Daily sessions | Albumin replacement